arrow
J

Joaquim Bosch-Barrera

asst dei sette laghi
H指数:38
被引数:5,759

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

pSTAT3 expression in patients with brain metastases from breast cancer: association with molecular subtypes and impact on overall survival

脑转移性乳腺癌患者中pSTAT3的表达:与分子亚型的关联及其对总生存期的影响

2025-11-010
OAAI
Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement

多学科方法治疗早期和局部晚期非小细胞肺癌(NSCLC)患者:西班牙肺癌组(GECP)第二届专家共识声明

2025-09-300
PRE
Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain

肺癌幸存者中第二原发癌的发病率:按肿瘤学治疗的西班牙全国前瞻性队列研究

2025-08-120
OA
STAT3 expression in brain metastases from breast cancer is correlated with molecular subtype and impacts clinical outcome

乳腺癌脑转移灶中STAT3的表达与分子亚型相关,并影响临床结局。

2025-08-010
PRE
Biomarker landscape in advanced NSCLC: insights from a national prospective registry

晚期NSCLC中的生物标志物图谱:一项全国性前瞻性注册研究的见解

2025-07-280
PRE
ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/ carboplatin in patients with squamous non-small cell lung cancer

ENDOLUNG试验,第二部分。一项关于Akt/mTOR抑制剂和自噬诱导剂ibrilatazar(ABTL0812)与紫杉醇/卡铂联合治疗鳞状非小细胞肺癌患者的II期研究。

2025-03-010
OAAI
Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry
2024-10-010
OAAI
Efficacy and safety of sunvozertinib in prior platinum treated NSCLC patients with EGFR exon 20 insertion mutations: Primary analysis from the multinational WU-KONG1B pivotal study

舒沃哲在既往接受铂类治疗的、携带EGFR外显子20插入突变的NSCLC患者中的疗效与安全性:跨国WU-KONG1B关键性研究的主要分析

2024-09-011
PRE
CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatment

关键:根据治疗方式分析西班牙胸肿瘤登记处的第二原发癌发生率

2024-09-010
PRE
A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer (vol 24, 876, 2024)
2024-07-290
OAAI
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer
2024-07-223
OAAI